Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Insights into the Functional Anatomy Behind the PREEMPT Injection Paradigm: Guidance on Achieving Optimal Outcomes.

Blumenfeld AM, Silberstein SD, Dodick DW, Aurora SK, Brin MF, Binder WJ.

Headache. 2017 May;57(5):766-777. doi: 10.1111/head.13074. Epub 2017 Apr 6.

2.

Technique of injection of onabotulinumtoxin A for chronic migraine: the PREEMPT injection paradigm.

Liberini P, Pari E, Gazzina S, Caratozzolo S, Rao R, Padovani A.

Neurol Sci. 2014 May;35 Suppl 1:41-3. doi: 10.1007/s10072-014-1740-6.

PMID:
24867834
3.

An academic debate: OnabotulinumtoxinA for chronic migraine: PREEMPT-derived vs "customized" dosing/injection paradigm.

Green MW, Rothrock JF.

Toxicon. 2018 Jun 1;147:116-119. doi: 10.1016/j.toxicon.2018.03.011. Epub 2018 Mar 27. Review.

PMID:
29596847
4.

Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program.

Blumenfeld A, Silberstein SD, Dodick DW, Aurora SK, Turkel CC, Binder WJ.

Headache. 2010 Oct;50(9):1406-18. doi: 10.1111/j.1526-4610.2010.01766.x.

PMID:
20958294
5.

Utilization and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine from an observational study in Europe.

Matharu M, Pascual J, Nilsson Remahl I, Straube A, Lum A, Davar G, Odom D, Bennett L, Proctor C, Gutierrez L, Andrews E, Johannes C.

Cephalalgia. 2017 Dec;37(14):1384-1397. doi: 10.1177/0333102417724150. Epub 2017 Jul 31.

6.

The Practical Use of AbobotulinumtoxinA in Aesthetics.

Kane MA, Monheit G.

Aesthet Surg J. 2017 May 1;37(suppl_1):S12-S19. doi: 10.1093/asj/sjw285. Review.

7.

Key Parameters for the Use of AbobotulinumtoxinA in Aesthetics: Onset and Duration.

Nestor M, Ablon G, Pickett A.

Aesthet Surg J. 2017 May 1;37(suppl_1):S20-S31. doi: 10.1093/asj/sjw282. Review.

8.

The impact of onabotulinumtoxinA on severe headache days: PREEMPT 56-week pooled analysis.

Matharu M, Halker R, Pozo-Rosich P, DeGryse R, Manack Adams A, Aurora SK.

J Headache Pain. 2017 Dec;18(1):78. doi: 10.1186/s10194-017-0784-4. Epub 2017 Aug 1.

9.

OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program.

Aurora SK, Dodick DW, Diener HC, DeGryse RE, Turkel CC, Lipton RB, Silberstein SD.

Acta Neurol Scand. 2014 Jan;129(1):61-70. doi: 10.1111/ane.12171. Epub 2013 Sep 20.

10.

Quarterly repeat cycles of onabotulinumtoxinA in chronic migraine patients: the benefits of the prolonged treatment on the continuous responders and quality-of-life conversion rate in a real-life setting.

Santoro A, Fontana A, Miscio AM, Zarrelli MM, Copetti M, Leone MA.

Neurol Sci. 2017 Oct;38(10):1779-1789. doi: 10.1007/s10072-017-3054-y. Epub 2017 Jul 19.

11.

Botulinum toxin for chronic migraine: Clinical trials and technical aspects.

Tassorelli C, Sances G, Avenali M, De Icco R, Martinelli D, Bitetto V, Nappi G, Sandrini G.

Toxicon. 2018 Jun 1;147:111-115. doi: 10.1016/j.toxicon.2017.08.026. Epub 2017 Sep 4. Review.

PMID:
28877509
12.

Effects of onabotulinumtoxinA treatment on efficacy, depression, anxiety, and disability in Turkish patients with chronic migraine.

Demiryurek BE, Ertem DH, Tekin A, Ceylan M, Aras YG, Gungen BD.

Neurol Sci. 2016 Nov;37(11):1779-1784. Epub 2016 Jul 14.

PMID:
27418178
13.

Development of onabotulinumtoxinA for chronic migraine.

Whitcup SM, Turkel CC, DeGryse RE, Brin MF.

Ann N Y Acad Sci. 2014 Nov;1329:67-80. doi: 10.1111/nyas.12488. Epub 2014 Aug 18. Review.

14.

[What is the optimal dose for the prophylactic treatment of chronic migraine patients?].

Irimia P, Esteve-Belloch P, Murie-Fernandez M, Martinez-Vila E.

Rev Neurol. 2014 Mar 10;58 Suppl 2:S13-9. Review. Spanish.

15.

OnabotulinumtoxinA for Treatment of Moderate to Severe Crow's Feet Lines: A Review.

Carruthers A, Bruce S, Cox SE, Kane MA, Lee E, Gallagher CJ.

Aesthet Surg J. 2016 May;36(5):591-7. doi: 10.1093/asj/sjw025. Epub 2016 Mar 15. Review.

PMID:
26979457
16.

OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.

Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, Diener HC, Brin MF; PREEMPT Chronic Migraine Study Group.

Headache. 2010 Jun;50(6):921-36. doi: 10.1111/j.1526-4610.2010.01678.x. Epub 2010 May 7.

PMID:
20487038
18.

Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study.

Blumenfeld AM, Stark RJ, Freeman MC, Orejudos A, Manack Adams A.

J Headache Pain. 2018 Feb 5;19(1):13. doi: 10.1186/s10194-018-0840-8.

19.

OnabotulinumtoxinA (BOTOX®): a review of its use in the prophylaxis of headaches in adults with chronic migraine.

Frampton JE.

Drugs. 2012 Apr 16;72(6):825-45. doi: 10.2165/11208880-000000000-00000. Review.

PMID:
22468643
20.

OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program.

Aurora SK, Winner P, Freeman MC, Spierings EL, Heiring JO, DeGryse RE, VanDenburgh AM, Nolan ME, Turkel CC.

Headache. 2011 Oct;51(9):1358-73. doi: 10.1111/j.1526-4610.2011.01990.x. Epub 2011 Aug 29.

PMID:
21883197

Supplemental Content

Support Center